-
Dr Reddy’s Laboratories reported a steep 69% YoY drop in consolidated net profit for Q1 FY27, hit by weak North America sales, lower global generics revenue, and supply disruptions of semaglutide. Shares closed 2.16% lower on the NSE.
-
This launch follows Dr Reddy's recent generic semaglutide injection launches in India and Canada, Dr Reddy's Laboratories Ltd (DRL) said in a statement
-
Dr Reddy’s Laboratories reported an 86 per cent decline in consolidated profit after tax for the March quarter at Rs 221.3 crore, mainly due to lower generics sales in North America. The company, however, recorded growth in India and European generics businesses
-
Dr Reddy’s Laboratories reported a 14 per cent decline in consolidated profit after tax at Rs 1,210 crore for the December 2025 quarter, impacted by weaker sales in the US and price erosion in key products.
-
In a statement, Dr Reddy's Laboratories clarified that with timely detection and swift action by the company's teams and banking partners, the funds have been frozen and that there was no financial loss
-
As per its latest Enforcement Report, USFDA said a US-based subsidiary of the Hyderabad-based drug major is recalling certain batches of a generic antiepileptic drug in the US market.
-
Ink licence agreement to develop and commercialise cancer drug HLX15
-
Market valuation eroded by Rs 5,399.33 crore to Rs 1,02,187.12 crore
-
Equipped with advanced technology and instruments, the centre offers comprehensive chemical, biological, and physical testing of soil testing of over 18 parameters, including primary, macro, and micronutrients, as well as heavy metals in soil, water, and plants
-
Under the agreements, MSN Laboratory will establish a manufacturing unit along with a Research & Development (R&D) center. Laurus Labs and Aurobindo Pharma will set up formulation units. Gland Pharma has shown interest in opening an R&D center, as well as manufacturing units for injectables and drug substances. Dr. Reddy's Labs plans to establish a unit for injectables and biosimilars. Hetero Labs will set up a plant for finished dose and injectable manufacturing.
-
Penalty imposed on the company for deviation from prescribed guidelines in filing intimation of import of a reference standard for one of the APIs
-
The proposed acquisition will be inclusive of all formats such as lozenge, patch, gum as well as pipeline products, in all applicable global markets outside of the United States.
-
The pharma firm had approached the Drugs Controller General of India (DCGI)seeking a waiver for the phase-III clinical trial of the drug and its market authorisation.
-
According to Dr. Reddy's, $90 million will be paid upfront in cash and there will be contingent payments of up to $15 million, towards inventory and credits for certain accrued channel liabilities to be determined on the closing date.
-
Dr Reddy's Laboratories reduced the price of its cardiovascular drug Cidmus, MSN Group, launched the world’s first generic Palbociclib tablets for advanced breast cancer therapy
-
Hyderabad: Pharma major Dr Reddy’s Laboratories (DRL) reported a profit after tax of Rs 1,188 crore for the June quarter. This is an increase of Rs 108% from Rs 570.8 crore during the corresponding period last year. Its revenues during the June quarter were Rs 5,215 crore, up 6% from Rs 4,919 crore. During the […]
-
Hyderabad: Dr. Reddy’s Laboratories is conducting a job mela for science students of Dr. BR Ambedkar Open University (BRAOU) in the Department of Chemistry on the university campus on Tuesday. To attend the job mela, candidates should have 60 per cent marks in SSC, intermediate and BSc Chemistry should be one of the subjects in […]
-
New Delhi: Dr Reddy’s Laboratories on Tuesday said it has launched Sorafenib tablets, used in the treatment of various cancers, in the US market after getting approval from the US Food and Drug Administration (USFDA). “We are pleased to launch this important generic product, illustrating our continued commitment to bring affordable generic medicines to market […]
-
Hyderabad: Covid has tested and proved the credibility of the Indian pharma industry as one of the core sectors for the nation. The industry rose to the occasion by ramping up research and manufacturing to find solutions for the treatment. Pharma companies are optimistic that normalcy will return in the next one year. Speaking at […]
-
Hyderabad: Indian pharma needs to move from low-risk research and innovation to high-risk research and innovation. And that’s where the country is lagging. Investing in high-risk innovation is very capital intensive and the return on that investment is both uncertain and long-term. To aid innovation, there needs to be adequate risk capital and a different […]
